"Shareholder approval will not be sought for the issue of options (or their exercise) as Dr Thadhani was not a director of Orthocell at the time of the negotiations and had no influence over the decision to issue the options".
Management just tossing around shares.
What is a reasonable timeframe for an experienced man like Ravi to have a director's role on a pissant ($75m Mcap) aussie bio before he resigns due to 'family reasons' and converts and sells up? I bet he is a board member or director of a dozen or more companies.
Sorry for being so cynical (LTHs) would undertand). I hope he is actually able to expose OCC to the right people and most importantly, investors or partners.
Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani, page-19
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
-0.005(1.16%) |
Mkt cap ! $89.07M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 43.0¢ | 42.0¢ | $90.9K | 214.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12850 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 24056 | 2 |
View Market Depth
| Last trade - 15.54pm 27/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |